COGT (Cogent Biosciences) Marketable Securities: $625.17 Mil (As of Mar. 2026)


COGT Cogent Biosciences Inc COGT
30 GF Score
Price $39.14
! 4 Warning Signs
View Full Analysis

What is Cogent Biosciences Marketable Securities?

Cogent Biosciences COGT -2.17% 30 Marketable Securities is $625.17 Mil as of Mar. 2026. GuruFocus rates COGT with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cogent Biosciences's Marketable Securities for the quarter that ended in Mar. 2026 was $625.17 Mil.

Cogent Biosciences's annual Marketable Securities declined from Dec. 2023 ($212.48 Mil) to Dec. 2024 ($188.91 Mil) but then increased from Dec. 2024 ($188.91 Mil) to Dec. 2025 ($588.75 Mil).

Cogent Biosciences  (NAS:COGT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Cogent Biosciences Marketable Securities Related Terms

Cogent Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences Marketable Securities Chart

Cogent Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 119.39 212.48 188.91 588.75

Cogent Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.66 110.25 265.59 588.75 625.17
COGT
30GF Score
Cogent Biosciences Inc COGT
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogent Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $625.17 Mil mean?
Cogent Biosciences (COGT) has a Marketable Securities of $625.17 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cogent Biosciences and its competitors.
Is Cogent Biosciences' Marketable Securities too high?
Cogent Biosciences' current Marketable Securities is $625.17 Mil. Overall, Cogent Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Marketable Securities compare to SRRK and CGON?
Cogent Biosciences' Marketable Securities of $625.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current Marketable Securities is $625.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Marketable Securities of $625.17 Mil. The current Marketable Securities is $625.17 Mil. Cogent Biosciences' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Marketable Securities is $625.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
30GF Score

Get the complete analysis for COGT

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.14
Price